2023-04-27 07:59:01 ET
- Clinical stage immuno-oncology company, Medicenna Therapeutics ( NASDAQ: MDNA ) received a notice from the Nasdaq granting the request for a 180-day extension to regain compliance with the minimum bid price requirement of $1 per share.
- The company was first notified by Nasdaq of its failure to comply with the minimum bid requirement on October 25, 2022, and was given until April 24, 2023 to regain compliance.
- The company now has until October 23, 2023 to meet the requirement.
For further details see:
Medicenna Therapeutics granted 180-day extension to meet Nasdaq complaince